Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA's Hamburg Says Japanese Crisis Shows Need To Fund Countermeasure Development

This article was originally published in The Pink Sheet Daily

Executive Summary

When Senators ask whether the U.S. is prepared for a nuclear disaster similar to one following the Japanese earthquake, FDA chief touts agency program that could help develop radiation treatments.

You may also be interested in...



Korean Pharmaceutical Association Urges People Not To Panic Over Iodide Products

SEOUL - To cope with rising requests for potassium iodide, the Korean Pharmaceutical Association has issued an appeal to the public, asking people not to panic about feared radiation exposure from Japan's earthquake-damaged nuclear power plants

Budget Pressures Are Hampering Science Efforts, FDA And NIH Heads Say

It will "certainly make it very hard to run an agency, when you don't know what your budget is, going forward," FDA Commissioner Margaret Hamburg says.

Capitol Hill In Brief

Congress passes CR with cuts to FDA

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS071967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel